99 related articles for article (PubMed ID: 19744626)
1. Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer.
Liljegren A; Bergh J; Castany R
Breast; 2009 Aug; 18(4):259-62. PubMed ID: 19744626
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib in breast cancer: friend or foe.
Cardoso F; Senkus-Konefka E
Breast; 2009 Aug; 18(4):211-2. PubMed ID: 19744625
[No Abstract] [Full Text] [Related]
3. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Bergh J; Mariani G; Cardoso F; Liljegren A; Awada A; Viganò L; Huang X; Verkh L; Kern KA; Giorgetti C; Gianni L
Breast; 2012 Aug; 21(4):507-13. PubMed ID: 22336056
[TBL] [Abstract][Full Text] [Related]
4. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Bergh J; Bondarenko IM; Lichinitser MR; Liljegren A; Greil R; Voytko NL; Makhson AN; Cortes J; Lortholary A; Bischoff J; Chan A; Delaloge S; Huang X; Kern KA; Giorgetti C
J Clin Oncol; 2012 Mar; 30(9):921-9. PubMed ID: 22331954
[TBL] [Abstract][Full Text] [Related]
6. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
Kozloff M; Chuang E; Starr A; Gowland PA; Cataruozolo PE; Collier M; Verkh L; Huang X; Kern KA; Miller K
Ann Oncol; 2010 Jul; 21(7):1436-1441. PubMed ID: 20032126
[TBL] [Abstract][Full Text] [Related]
7. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Rugo HS; Stopeck AT; Joy AA; Chan S; Verma S; Lluch A; Liau KF; Kim S; Bycott P; Rosbrook B; Bair AH; Soulieres D
J Clin Oncol; 2011 Jun; 29(18):2459-65. PubMed ID: 21555686
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Cumashi A; Tinari N; Rossi C; Lattanzio R; Natoli C; Piantelli M; Iacobelli S
Cancer Lett; 2008 Nov; 270(2):229-33. PubMed ID: 18586384
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.
Wildiers H; Fontaine C; Vuylsteke P; Martens M; Canon JL; Wynendaele W; Focan C; De Greve J; Squifflet P; Paridaens R
Breast Cancer Res Treat; 2010 Sep; 123(2):463-9. PubMed ID: 20652398
[TBL] [Abstract][Full Text] [Related]
10. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
Guérin O; Formento P; Lo Nigro C; Hofman P; Fischel JL; Etienne-Grimaldi MC; Merlano M; Ferrero JM; Milano G
J Cancer Res Clin Oncol; 2008 Jan; 134(1):51-7. PubMed ID: 17593391
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma.
Puente J; Manzano A; Martin M; López-Tarruella S; Díaz-Rubio E
Anticancer Drugs; 2010 Jan; 21 Suppl 1():S19-22. PubMed ID: 20110783
[TBL] [Abstract][Full Text] [Related]
12. Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer.
Baselga J; Smith BL; Rafferty EA; Bombonati A
N Engl J Med; 2012 May; 366(21):2018-26. PubMed ID: 22621630
[No Abstract] [Full Text] [Related]
13. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
14. Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate.
Saada E; Saint Paul MC; Gugenheim J; Follana P; François E
Oncol Res Treat; 2014; 37(3):124-6. PubMed ID: 24685916
[TBL] [Abstract][Full Text] [Related]
15. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
16. Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Wang D; Jiang Z; Zhang L
Med Oncol; 2012 Jun; 29(2):600-6. PubMed ID: 21455800
[TBL] [Abstract][Full Text] [Related]
17. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Polyzos A
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
[TBL] [Abstract][Full Text] [Related]
18. [Breast carcinoma and bone chondrosarcoma: a new syndrome?].
Guedin P; Chasle J; Blanc-Fournier C; Lacroix J
J Radiol; 2006 Nov; 87(11 Pt 1):1700-4. PubMed ID: 17095966
[TBL] [Abstract][Full Text] [Related]
19. Pseudocirrhosis in metastatic breast cancer.
Hidalgo-Blanco A; Aguirresarobe-Gil de San Vicente M; Aresti S; de Miguel E; Cabriada-Nuno JL
Gastroenterol Hepatol; 2018 Feb; 41(2):111-113. PubMed ID: 28187872
[No Abstract] [Full Text] [Related]
20. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Houk BE; Bello CL; Kang D; Amantea M
Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
